HUTCHMED (China) Limited
HUTCHMED (China) Limited has 1 licensing announcement in this dataset, dated 2023-01-23.
- Country / operating region
- China
- Ticker
- 00013.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.hutch-med.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| fruquintinib | VEGFR1/2/3 | small molecule | 查無 | 2023-01-23 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| fruquintinib | 查無 | — | 查無 | 查無 | 2023-01-23 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2023-01-23 | Takeda Pharmaceutical Company Limited | fruquintinib | USD 400m | 查無 | ≤ USD 730m | 查無 | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Worldwide excluding mainland China, Hong Kong and Macau | Royalties on net sales; rate not disclosed. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無